Allergan Newswire

Allergan Newswire

Comprehensive Real-Time News Feed for Allergan.

Results 1 - 20 of 2,193 in Allergan

  1. Allergan (AGN) Stake Boosted by Usca Ria LLCRead the original story w/Photo

    19 hrs ago | AmericanBankingNews.com

    Usca Ria LLC grew its position in shares of Allergan by 25.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,422 shares of the company's stock after acquiring an additional 1,287 shares during the period.

    Comment?

  2. ProVise Management Group LLC Acquires 1,620 Shares of AllerganRead the original story w/Photo

    19 hrs ago | AmericanBankingNews.com

    ProVise Management Group LLC raised its holdings in Allergan by 32.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,568 shares of the company's stock after acquiring an additional 1,620 shares during the quarter.

    Comment?

  3. Aperio Group LLC Has $17.72 Million Holdings in AllerganRead the original story w/Photo

    Yesterday | AmericanBankingNews.com

    Aperio Group LLC raised its position in shares of Allergan by 18.7% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 105,301 shares of the company's stock after buying an additional 16,561 shares during the period.

    Comment?

  4. Allergan (AGN) Expected to Post Quarterly Sales of $3.90 BillionRead the original story w/Photo

    Yesterday | IntersportsWire

    Analysts expect that Allergan will announce sales of $3.90 billion for the current quarter, Zacks Investment Research reports. Nineteen analysts have provided estimates for Allergan's earnings.

    Comment?

  5. Teacher Retirement System of Texas Has $20.94 Million Stake in AllerganRead the original story w/Photo

    Yesterday | Daily Political

    Teacher Retirement System of Texas lowered its stake in shares of Allergan by 3.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 124,399 shares of the company's stock after selling 4,124 shares during the period.

    Comment?

  6. KCM Investment Advisors LLC Acquires 6,448 Shares of AllerganRead the original story w/Photo

    Yesterday | AmericanBankingNews.com

    KCM Investment Advisors LLC lifted its stake in shares of Allergan by 16.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 44,783 shares of the company's stock after buying an additional 6,448 shares during the quarter.

    Comment?

  7. Lateef Investment Management L.P. Acquires 4,767 Shares of AllerganRead the original story w/Photo

    Yesterday | AmericanBankingNews.com

    Lateef Investment Management L.P. boosted its holdings in shares of Allergan by 3.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 164,319 shares of the company's stock after buying an additional 4,767 shares during the quarter.

    Comment?

  8. Allergan (AGN) Shares Bought by Korea Investment CORPRead the original story w/Photo

    Friday | IntersportsWire

    Korea Investment CORP increased its stake in Allergan by 1.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 246,813 shares of the company's stock after purchasing an additional 4,627 shares during the period.

    Comment?

  9. ITC Institutes Investigation Based on Allegation of Drug Sales Without FDA ApprovalRead the original story w/Photo

    Friday | JD Supra

    ... Thus, Valeant needed to show that the ITC's jurisdiction was not preempted by the FDCA. Valeant analogized to Allergan, Inc. v. Athena Cosmetics, Inc. , 738 F.3d 1350 (Fed. Cir. 2013), where the Federal Circuit held that state-law, ...

    Comment?

  10. Allergan (AGN) Given Buy Rating at Wells FargoRead the original story w/Photo

    Friday | IntersportsWire

    A number of other equities analysts also recently weighed in on the stock. Cowen set a $255.00 target price on shares of Allergan and gave the company a buy rating in a research note on Monday, April 16th.

    Comment?

  11. Allergan (AGN) Holdings Raised by Fulcrum Capital LLCRead the original story w/Photo

    Friday | AmericanBankingNews.com

    Fulcrum Capital LLC raised its position in Allergan by 14.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,778 shares of the company's stock after purchasing an additional 1,342 shares during the period.

    Comment?

  12. Head to Head Review: Allergan (AGN) versus Its PeersRead the original story w/Photo

    Friday | IntersportsWire

    Allergan is one of 488 publicly-traded companies in the "Pharmaceutical preparations" industry, but how does it compare to its rivals? We will compare Allergan to related businesses based on the strength of its earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability. 80.0% of Allergan shares are held by institutional investors.

    Comment?

  13. Big Pharmacy Retailers File Antitrust Lawsuit Against Allergan Over Restasis MarketingRead the original story w/Photo

    Thursday | Vision Monday

    Four of the nation's largest pharmacy operators have filed an antitrust lawsuit in U.S. District Court here accusing Allergan plc of an "unlawful scheme to maintain its monopoly in the market" for dry-eye treatment Restasis in the U.S. The four retailers-Walgreen Co., Kroger Co., Albertsons Cos. Inc. and HEB Grocery Co.-allege antitrust violations by the pharmaceutical company.

    Comment?

  14. Allergan (AGN) vs. Its Peers Head to Head SurveyRead the original story w/Photo

    Thursday | AmericanBankingNews.com

    Allergan is one of 488 publicly-traded companies in the "Pharmaceutical preparations" industry, but how does it compare to its rivals? We will compare Allergan to related companies based on the strength of its earnings, valuation, risk, profitability, analyst recommendations, dividends and institutional ownership. Allergan has higher revenue, but lower earnings than its rivals.

    Comment?

  15. Facebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMIRead the original story

    Thursday | TheStreet.com

    ... macro trends such as the aforementioned rise in oil prices and the threat of inflation that could weigh on margins. Allergan ( AGN ) is facing some pressures to its Botox franchise. But as a competitor to Allergan's Botox faces a regulatory delay in ...

    Comment?

  16. Allergan's Meury Talks Market Expansion in AestheticsRead the original story

    Thursday | TheStreet.com

    As a competitor to Allergan plc's Botox faces a delay in getting to market, Allergan is anything but frozen. "Of course, it's always interesting when a company takes more time to get to market," Allergan chief commercial officer William Meury said at the Bank of America healthcare conference in Las Vegas on Thursday, May 17. "It doesn't hurt our business, but to be fair we have to be focused on something bigger, which is market expansion."

    Comment?

  17. Allergan (AGN) Shares Sold by Rothschild Asset Management Inc.Read the original story w/Photo

    Thursday | IntersportsWire

    Rothschild Asset Management Inc. decreased its holdings in shares of Allergan by 3.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 224,120 shares of the company's stock after selling 7,447 shares during the quarter.

    Comment?

  18. Sector Gamma AS Has $10.82 Million Stake in AllerganRead the original story w/Photo

    Thursday May 17 | AmericanBankingNews.com

    Sector Gamma AS lifted its stake in shares of Allergan by 2.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 64,300 shares of the company's stock after purchasing an additional 1,700 shares during the period.

    Comment?

  19. Dorsey & Whitney Trust Co LLC Purchases New Holdings in AllerganRead the original story w/Photo

    Thursday May 17 | Daily Political

    Dorsey & Whitney Trust CO LLC purchased a new stake in Allergan during the first quarter, Holdings Channel reports. The fund purchased 1,275 shares of the company's stock, valued at approximately $216,000.

    Comment?

  20. Teva's Generic Restasis Could Punish AllerganRead the original story w/Photo

    Thursday May 17 | Seeking Alpha

    Teva's generic Restasis will provide headwinds and could pressure lawmakers to approve a generic version in the U.S. Last week Teva announced it had launched a generic version of Allergan's blockbuster dry-eye drug Restasis in Canada: Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced the launch of Teva-CyclosporineA ophthalmic emulsion, 0.05% w/v , a Health Canada approved twice-daily eye drop solution and the first generic version of RestasisA in Cyclosporine ophthalmic emulsion is indicated for the treatment of moderate to moderately severei aqueous deficient dry eye disease, characterized by moderate to moderately severe: ocular staining, reduction in tear production and fluctuating visual symptoms, such as blurred vision.

    Comment?